Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement
出版年份 2023 全文链接
标题
Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume -, Issue -, Pages 1-11
出版商
Informa UK Limited
发表日期
2023-10-30
DOI
10.1080/14728222.2023.2277224
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics
- (2023) Esther Stern et al. Frontiers in Immunology
- Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
- (2023) Gaurav Kumar Pandey et al. Cell Reports Medicine
- Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity
- (2023) Lise Mangiante et al. NATURE GENETICS
- Functional precision oncology using patient-derived assays: bridging genotype and phenotype
- (2023) Allard W. J. van Renterghem et al. Nature Reviews Clinical Oncology
- ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
- (2023) Santiago Ponce et al. Journal for ImmunoTherapy of Cancer
- Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
- (2022) Dean A Fennell et al. LANCET ONCOLOGY
- EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
- (2022) Marjorie G Zauderer et al. LANCET ONCOLOGY
- Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
- (2022) Hedy L Kindler et al. LANCET ONCOLOGY
- Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial
- (2022) Mario Ghosn et al. LUNG CANCER
- A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma
- (2022) Irene Dell’Anno et al. Cancers
- Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
- (2022) Jean-Baptiste Assié et al. Cancers
- Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
- (2022) Tomer Meirson et al. JAMA Network Open
- YAP1 is essential for malignant mesothelioma tumor maintenance
- (2022) Loreley Calvet et al. BMC CANCER
- Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)
- (2022) Benjamin Zagiel et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4 /6 inhibition
- (2022) Sabine Paternot et al. Molecular Oncology
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
- (2021) Paul Baas et al. LANCET
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours
- (2021) Yordanos F.I. Setargew et al. Cancers
- CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials
- (2021) Navin K. Chintala et al. LUNG CANCER
- Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
- (2021) Dario P. Anobile et al. Cancers
- Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
- (2021) Sören Weidemann et al. Biomedicines
- NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
- (2021) Vilde Drageset Haakensen et al. Journal of Translational Medicine
- A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab
- (2021) Prasad S Adusumilli et al. Cancer Discovery
- Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
- (2021) Dean A Fennell et al. Lancet Respiratory Medicine
- Blocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma
- (2021) Meilin Chan et al. Communications Biology
- CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
- (2021) Pierpaolo Correale et al. LANCET ONCOLOGY
- Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
- (2021) Dean A Fennell et al. LANCET ONCOLOGY
- A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
- (2021) Aditya Wirawan et al. MOLECULAR CANCER RESEARCH
- Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival
- (2020) Lisa Quetel et al. Molecular Oncology
- PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.
- (2020) Patrick M. Forde et al. JOURNAL OF CLINICAL ONCOLOGY
- The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
- (2020) Christophe Blanquart et al. Frontiers in Oncology
- A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- (2020) S. Popat et al. ANNALS OF ONCOLOGY
- Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: First report of FAPME, a phase I clinical trial
- (2020) S. Hiltbrunner et al. ANNALS OF ONCOLOGY
- Oncolytic herpesvirus therapy for mesothelioma – A Phase I/IIa trial of intrapleural administration of HSV1716
- (2020) Sarah J Danson et al. LUNG CANCER
- Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
- (2019) Emanuela Cova et al. International Journal of Nanomedicine
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
- (2019) Yuna Blum et al. Nature Communications
- Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study
- (2019) Dean A. Fennell et al. JOURNAL OF CLINICAL ONCOLOGY
- Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma
- (2019) Raffit Hassan et al. CLINICAL CANCER RESEARCH
- Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling
- (2019) Jiao Wu et al. NATURE
- V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
- (2019) Stephanie Muller et al. MODERN PATHOLOGY
- NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma
- (2018) Tatsuhiro Sato et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion
- (2018) Charu Aggarwal et al. MOLECULAR THERAPY
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma
- (2018) Julija Hmeljak et al. Cancer Discovery
- Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma
- (2017) Peter W. Szlosarek et al. JAMA Oncology
- Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
- (2016) Robin Cornelissen et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN Combined with Chemotherapy
- (2016) D. H. Sterman et al. CLINICAL CANCER RESEARCH
- Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas
- (2016) Christelle Combaz-Lair et al. HUMAN PATHOLOGY
- Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model
- (2016) Lukasz Kuryk et al. INTERNATIONAL JOURNAL OF CANCER
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status
- (2016) Marie Schoumacher et al. NATURE MEDICINE
- MTAPdeletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
- (2016) Gregory V. Kryukov et al. SCIENCE
- Loss of BAP1 function leads to EZH2-dependent transformation
- (2015) Lindsay M LaFave et al. NATURE MEDICINE
- Germline Mutations in BAP1 Impair Its Function in DNA Double-Strand Break Repair
- (2014) I. H. Ismail et al. CANCER RESEARCH
- Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
- (2014) R. Hassan et al. CLINICAL CANCER RESEARCH
- Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
- (2014) Aurélien de Reyniès et al. CLINICAL CANCER RESEARCH
- Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
- (2014) I. M. Shapiro et al. Science Translational Medicine
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
- (2014) Scott J Dixon et al. eLife
- Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
- (2013) Sophie Papa et al. Journal of Thoracic Oncology
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
- (2013) Petra C Schuberth et al. Journal of Translational Medicine
- Fibroblast Activation Protein in Remodeling Tissues
- (2012) M. Jacob et al. CURRENT MOLECULAR MEDICINE
- BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma
- (2011) Sara Busacca et al. JOURNAL OF PATHOLOGY
- Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma
- (2010) Joost P. Hegmans et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
- (2010) Lee M. Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PRMT5 is required for cell-cycle progression and p53 tumor suppressor function
- (2009) A. Scoumanne et al. NUCLEIC ACIDS RESEARCH
- A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer
- (2008) Hedy Lee Kindler et al. INVESTIGATIONAL NEW DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now